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Background: Mammalian target of rapamycin (mTOR) inhibitors have anti-tumor effects against renal cell carcinoma,
pancreatic neuroendocrine cancer and breast cancer. In this study, we analyzed the antitumor effects of mTOR
inhibitors in small cell lung cancer (SCLC) cells and sought to clarify the mechanism of resistance to mTOR inhibitors.
Methods: We analyzed the antitumor effects of three mTOR inhibitors including everolimus in 7 SCLC cell lines by MTS
assay. Gene-chip analysis, receptor tyrosine kinases (RTK) array and Western blotting analysis were performed to identify
molecules associated with resistance to everolimus.
Results: Only SBC5 cells showed sensitivity to everolimus by MTS assay. We established two everolimus resistant-SBC5
cell lines (SBC5 R1 and SBC5 R10) by continuous exposure to increasing concentrations of everolimus stepwise.
SPP1 and MYC were overexpressed in both SBC5 R1 and SBC5 R10 by gene-chip analysis. High expression levels
of eukaryotic translation initiation factor 4E (eIF4E) were observed in 5 everolimus-resistant SCLC cells and SBC5
R10 cells by Western blotting. MYC siRNA reduced eIF4E phosphorylation in SBC5 cells, suggesting that MYC
directly activates eIF4E by an mTOR-independent bypass pathway. Importantly, after reduction of MYC or eIF4E
by siRNAs, the SBC5 parent and two SBC5-resistant cells displayed increased sensitivity to everolimus relative to
the siRNA controls.
Conclusion: These findings suggest that eIF4E has been shown to be an important factor in the resistance to
everolimus in SCLC cells. Furthermore, a link between MYC and mTOR-independent eIF4E contribute to the
resistance to everolimus in SCLC cells. Control of the MYC-eIF4E axis may be a novel therapeutic strategy for
everolimus action in SCLC.
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Lung cancer is a leading cause of death in Japan and the
world [1]. Small cell lung cancer (SCLC), which is char-
acterized as a neuroendocrine tumor, is one of the most
aggressive cancers and is often diagnosed only in late
stages. Metastases are frequently found on initial diagnosis
of SCLC patients. Chemotherapy has a major role in treat-
ment in advanced SCLC patients. Chemotherapy with
cisplatin and etoposide or irinotecan has yielded the best
outcomes in SCLC [2]; however, the major concern with
these treatments is the short duration of response.* Correspondence: mseike@nms.ac.jp
Department of Pulmonary Medicine and Oncology, Graduate School of
Medicine, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo
113-8603, Japan
© 2015 Matsumoto et al.; licensee BioMed Ce
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Molecularly-targeted therapies have been recently devel-
oped for non-small cell lung cancer (NSCLC) treatment.
Oncogenic driver mutations including Epidermal growth
factor receptor (EGFR) gene mutation and ALK transloca-
tion have been commonly found in NSCLC [3-5]. Recent
randomized trials using gefitinib, erlotinib, afatinib, and cri-
zotinib have demonstrated significant superiority of these
molecularly-targeted drugs on progression-free survival
compared with standard chemotherapies as key agents for
advanced NSCLC with driver mutations [6-8]. However,
there are oncogenic driver mutations found in SCLC,
but they have not been successfully targeted. Therefore,
molecularly-targeted agents developed for NSCLC are
largely ineffective against SCLC. New targeted drugs are
required for therapeutic strategies in SCLC.ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cin (mTOR) inhibitor. It is approved for treatment of ad-
vanced renal cell carcinoma, pancreatic neuroendocrine
cancer and breast cancer [9-11]. mTOR is expressed in
approximately 50% of SCLC tumors, suggesting that the
phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR path-
way is frequently activated in SCLC [12]. Everolimus
has been evaluated as second-line therapy for SCLC in a
phase II study [13]. One partial response was observed
in a patient with sensitive relapse with an objective re-
sponse rate of 3%. Disease control rate (DCR) at 6 weeks
was 26%. Median survival was 6.7 months and median
time to progression was 1.3 months. Baseline S6K ex-
pression was associated with DCR. Although the antitu-
mor effect of everolimus was limited in that study,
further evaluation of everolimus has been performed in
combination regimens for SCLC patients designed to
overcome drug resistance [14,15]. Therefore, identifica-
tion of biomarkers predictive of sensitivity to everoli-
mus could have a clinically significant impact on SCLC
treatment strategies.
In this study, we analyzed the antitumor effects of
three mTOR inhibitors including everolimus in SCLC
cell lines and sought to clarify the mechanism of resist-
ance to everolimus and thereby overcome such resistance.
We ultimately found that MYC and eukaryotic translation
initiation factor 4E (eIF4E) collaborate to offset the antitu-




We used 7 SCLC cell lines in this study. SBC3 and SBC5
were purchased from the Japanese Collection of Re-
search Bioresources Cell Bank (Osaka, Japan). H69 and
N231 were purchased from the American Type Culture
Collection (Manassas, VA). MS1 and Lu139 were obtained
from the Riken Cell Bank (Tsukuba, Japan). PC6 was
purchased from Immuno-Biological Laboratories (Gunma,
Japan). SBC5 and SBC3 were maintained in MEM-EAGLE
medium (Sigma-Aldrich, Tokyo, Japan) with 10% fetal
bovine serum (FBS; Gemini Bioproducts). The other
SCLC cell lines were maintained in RPMI 1640 (GIBCO,
Carlsbad, CA) with 10% FBS. These cell lines were ob-
tained from 2008 to 2009, amplified and frozen, and one
aliquot of each was thawed for this project. All cells
were routinely screened for the absence of mycoplasma.
Drugs and growth-inhibition assay
Everolimus, temsirolimus and rapamycin were purchased
from Selleck Chemicals (S1120, S1044 and S1039)
(Houston, TX). Growth inhibition was assessed by the
MTS assay to examine the effect of everolimus, temsiro-
limus and rapamycin on SCLC cell lines as previouslydescribed [16]. Cell suspensions (5,000 cells/well) were
seeded into 96-well plates and increasing concentrations
of everolimus, temsirolimus and rapamycin (0, 0.001,
0.01. 0.1, 1.0, 10 and 100 μM) were added. After incuba-
tion at 37 °C for 72 h, MTS was added to each well and
incubated at 37 °C for 2 h, after which absorbance was
measured at a test wavelength of 490 nm using a micro-
plate reader (Dynatech MR7000, Dynatech, Billinghurst,
UK). The IC50 value was defined as the concentration
of everolimus, temsirolimus or rapamycin needed for
50% reduction of growth and was calculated by Sigma-
Plot12 (HULINKS, Inc, Tokyo, Japan). Each experiment
was performed independently three times. The corrected
absorbance of each sample was calculated and compared
with that of the untreated control.
RNA isolation, cDNA array and RTKs phosphorylation
antibody array
Total RNA was isolated from SCLC cell lines, as previously
described [17,18]. High-density oligonucleotide array ana-
lysis was carried out using Affymetrix HG-U133A Gene-
Chips (22,282 probe sets), as previously described [19]. We
also performed human receptor tyrosine kinases (RTKs)
phosphorylation antibody arrays, including 71 antibodies
(RayBiotech, Inc. Norcross GA).
Western blot analysis
Cells were lysed in buffer containing 50 mM Tris–HCl,
pH 7.6, 150 mM NaCl, 0.1% sodium dodecyl sulfate, 1%
Nonidet P-40, and 0.5% sodium deoxycholate. Western
blot analysis was performed as previously described
[18]. Antibodies detecting phosphorylated-AKT (p-AKT,
Ser473), AKT, phosphorylated-EGFR (p-EGFR), EGFR,
mTOR, phosphorylated-4E-BP1 (p-4E-BP1), 4E-BP1, c-
MYC, phosphorylated-eIF4E were purchased from Cell
Signaling Technology (Beverly, MA); Cat No. #9271,
#9272, #2234, #2232, #2983, #2855, #9644, #9552, #9402,
#9402. Antibody targeting β-actin was purchased from
Sigma; Cat No. A5316.
Oligonucleotide transfection
Small interfering RNAs (siRNAs) targeting MYC and eIF4E
were purchased from Ambion (CA); c-MYC: Cat No. A)
s9129, B) s9130; eIF4E: Cat No. A) s4576, B) s4577
and homologous negative controls were obtained from
Invitrogen. siRNAs of MYC and eIF4E were transfected
using Lipofectamine 2000 reagent 24 hours after seeding,
according to the manufacturer’s instructions (Life Tech-
nologies, Carlsbad, CA). Transfections of siRNA complexes
were added to cells at a final concentration of 50 nM.
Fluorescence in situ hybridization (FISH)
Gene copy numbers (GCNs) and amplification of MYC
gene were examined by FISH. Tissue sections were then
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(LSI Medience Corporation, Chiba, Japan). Numbers of
fluorescence signals were counted independently by two
investigators using an Axio Vision microscope (Carl Zeiss,
Oberkochen, Germany).
Results
Effects of mTOR Inhibitors on Small Cell Lung Cancer
Cells and protein expressionn of AKT/mTOR pathway
molecules
We examined the anti-tumor activities of three mTOR
inhibitors including everolimus, temsirolimus and rapa-
mycin against 7 SCLC cell lines by MTS assay (Figure 1A).
Significant correlation of drug sensitivities was observed
among the three mTOR inhibitors by Spearman correl-
ation (Figure 1B). With reference to the Cmax of everoli-
mus (70 nM), the 7 cell lines were classified as sensitive
(IC50 ≤ 70 nM) or resistant (IC50 > 70 nM) to everolimus.
Only SBC5 cells showed sensitivity to everolimus, whereas
the other 6 cell lines showed resistance (Figure 1A). IC50
value of SBC5 cells for everolimus, temsirolimus and rapa-
mycin were 4.9 nM, 9.3 nM, and 334 nM, respectively.
We next evaluated protein expression levels of AKT/Figure 1 Effects of mTOR inhibitors on SCLC cell lines and protein ex
7 SCLC cell lines responding to mTOR inhibitor treatments by MTS assay. (B
everolimus and temsirolimus. (C) Protein expression of PI3K/mTOR pathwamTOR signal pathway molecules in the 7 SCLC cell lines
by Western blot analysis (Figure 1C). Expression levels of
p-AKT, AKT and mTOR did not differ remarkably among
the 7 cell lines. Although expression of eukaryotic trans-
lation initiation factor 4E (eIF4E), a downstream com-
ponent of the AKT/mTOR pathway, was not detected in
SBC5 cells, its expression was remarkably increased in
everolimus-resistant cells, with the exception of H69
cells. The IC50 value of H69 cells was lowest among 6
everolimus-resistant SCLC cells. However, high expres-
sion of p-AKT, the mTOR upstream molecule, was
observed in H69 cells. Overexpression of p-AKT may
affect the resistance to everolimus in H69 cells.
Establishment of Everolimus-Resistant SBC5 Cells
and Identification of Genes and RTK Associated with
Resistance to Everolimus
To clarify the mechanism of resistance to everolimus, we
sought to establish everolimus-resistant SBC5 cells by
continuous exposure to increasing concentrations of evero-
limus stepwise. After two months, we established two
SBC5-resistant cell lines which survived in either 1 μM
(SBC5 R1), or 10 μM everolimus (SBC5 R10) (Figure 2A).pression of PI3K/mTOR pathway molecules. (A) IC50 values for
) Spearman correlation showed significant correlation between
y molecules in 7 SCLC cells by Western blot analysis.
Figure 2 Characteristics of SBC5 R1 and SBC5 R10 cells. (A) MTS assays with everolimus in SBC5, SBC5 R1 and SBC5 R10 cells. Data are
expressed as the mean ± SD from 3 independent experiments. (B) Differentially expressed genes between SBC5 parent and SBC5 resistant cells
by Gene-chip analysis (Fold change >10, <-10). (C) RTK phosphorylation associated with everolimus resistance in SBC5 cells. Ten differentially
expressed RTKs between SBC5 parent and SBC5 R1 cells by RTK array (Fold change >1.5, <0.8). Only p-EGFR was overexpressed in both SBC5 R1
and SBC5 R10 cells (1.82-fold and 1.55-fold, respectively). (D) Protein expressions of three candidate molecules in SCLC cells by Western blot
analysis. p-EGFR, EGFR, MYC and SPP1 were elevated in the two everolimus-resistant SBC5 cells. (E) FISH analysis for MYC. Red signal indicates
8q24. Green signal indicates D8Z2 probe (8cen). No evidence of MYC overexpression was found.
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vestigations. First, we performed gene expression profiles
by Gene-Chip analysis to identify genes associated with re-
sistance to everolimus. Expression of 19 genes differedsignificantly between parent SBC5 cells and SBC5 R1/
SBC5 R10 cells (Fold change >10, <-10) (Figure 2B).
Among the 19 genes, SPP1 and MYC were significantly
overexpressed in both resistant cells. Second, we evaluated
Figure 3 MYC and eIF4E contribute to the acquired resistance
to Everolimus. (A) Protein expression of PI3K/mTOR pathway
molecules in SCLC cells by Western blot analysis. p-eIF4E was significantly
elevated in the two everolimus-resistant SBC5 cells. (B) Silencing of MYC
by two siRNAs in SBC5 cells. p-eIF4E were decreased by si-MYC-A and
si-MYC-B at 72 hours. (C) Silencing of MYC by two siRNAs in SBC5 R1 cells
in the presence of everolimus 1uM. p-eIF4E protein levels were decreased
by the treatments with the two si-MYCs at 48 hours. Eve: Everolimus.
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cells versus parental SBC5 cells by RTK array (Figure 2C).
Ten RTK were significantly changed in SBC5 R1 cells com-
pared with parent SBC5 cells (Fold change >1.5, <0.8).
Among the 10 RTK, only p-EGFR was also upregulated in
SBC5 R10 cells (Fold change, 1.55). Based on these results,
we focused on p-EGFR, SPP1 and MYC as everolimus-
resistant candidate molecules. We next confirmed protein
expression levels of p-EGFR, EGFR, SPP1 and MYC in
SCLC cells by Western blot analysis (Figure 2D). p-EGFR
and EGFR levels were increased in SBC5 R1 and SBC5
R10 cells compared to the parent cells. SPP1 and MYC
were also elevated in SBC5 R1 and R10 cells with respect
to the parent SBC5 cells. SPP1 as well as EGFR are known
as upstream molecules of AKT/mTOR signaling and can
activate downstream signals [20,21]. Overexpression of p-
EGFR and SPP1 may be a result of negative-feedback ef-
fects of mTOR inhibition. In contrast, MYC can directly
activate eIF4E, the most mTOR downstream molecule, via
a bypass pathway [22]. We examined by FISH whether
MYC amplification was observed as the mechanism of
MYC overexpression in resistant cells. However, MYC gene
amplification was not observed in either SBC5 resistant cell
type (Figure 2E).
MYC and eIF4E Contribute to Acquired Resistance to
Everolimus
We next examined protein expression levels of AKT/
mTOR signal pathway molecules in both SBC5 resistant
cells by Western blot analysis (Figure 3A). p-AKT, AKT
and mTOR expression levels did not differ between parent
SBC5 and SBC5 R1/R10 cells. In contrast, PTEN protein
levels were decreased in both resistant cells. Suppression
of PTEN resulting in AKT activation may be a result of
negative-feedback effects of mTOR inhibition. Further-
more, eIF4E expression was elevated in SBC5 R10 cells
over levels in parent SBC5 cells. Gene-chip analysis also
revealed that resistance to everolimus resulted in increased
eIF4E gene expression in SBC5 R1 and R10 cells by 2.86
and 2.86-fold, respectively (data not shown). A previous
study demonstrated that eIF4E was directly regulated by
MYC [22]. Expression levels of p-4E-BP1, an upstream
direct inhibitor of eIF4E, were not changed in SBC5 R1
and R10 cells over levels in parent SBC5 cells (Figure 3A).
These findings suggest that eIF4E may be directly regu-
lated by a ‘bypassing’ pathway involving MYC in SBC5
resistant cells. Therefore, to further evaluate the effects of
MYC and eIF4E on resistance to everolimus, MYC siRNAs
were transfected into SBC5 and SBC5 R10 cells to examine
whether MYC directly regulated eIF4E in the resistance to
everolimus. Western blotting revealed that two si-MYCs
reduced eIF4E phosphorylation in SBC5 cells (Figure 3B).
AKT was overexpressed in SBC5 R1 cells treated with two
si-MYCs in the presence of 1 μM everolimus (Figure 3C).Importantly, MYC was silenced in SBC5 R1 cells exposed
to everolimus, showing decreased levels of p-eIF4E and no
differences in levels of mTOR, or p-4E-BP1 (Figure 3C).
These results suggest that eIF4E is directly activated by
MYC in SBC5 and SBC5 resistant cells.
Overcoming Resistance to Everolimus using MYC and
eIF4E siRNAs
Finally, we evaluated whether silencing of MYC and eIF4E
could overcome the resistance to everolimus. SBC5 cells
with reduced MYC or eIF4E following transfection with
siRNAs displayed increased sensitivity to everolimus rela-
tive to siRNA controls (Figure 4A). Interestingly, SBC5 R1
Figure 4 MYC and eIF4E silencing increases the sensitivity to everolimus in SBC5 parent cells (SBC5) (A), SBC5 R1 cells (B), and SBC5
R10 cells (C) by MTS assay. Data are expressed as the mean ± SD from 3 independent experiments. (D) Schematic of the results. eIF4F
expression can be up-regulated by the PI3K/AKT/mTOR-dependent pathway by p-EGFR activation, PTEN suppression, and SPP1 overexpression.
In contrast, MYC directly activates eIF4E expression by an mTOR-independent bypassing pathway.
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versed resistance to everolimus relative to siRNA controls
(Figure 4B, C). These results suggest that MYC and eIF4E
collaborate in drug resistance to everolimus, apparently
bypassing the inhibitors in an mTOR-independent man-
ner in SCLC cells (Figure 4D).
Discussion
The commonly observed activated PI3K/AKT/mTOR
pathway contributes to cancer development and main-
tenance in SCLC [12]. Activation of AKT through PI3K
leads to increased mTOR activity through signaling by
means of the TSC1/2 complex. mTOR phosphorylates
S6K1 and 4E-BP1, and the most downstream effector,
eIF4E. In this study, eIF4E levels were increased in 5
everolimus-resistant SCLC cell lines and in SBC5 R10 cells
during everolimus therapy. eIF4E expression can be acti-
vated by mTOR-dependent and mTOR-independent path-
ways. Overexpression of p-EGFR and decreased PTEN
can activate eIF4E through activation of the PI3K/AKT/
mTOR pathway. Previous reports have demonstrated that
SPP1 can also activate p-AKT and downstream molecules
including eIF4E [20,21]. In contrast, we found that MYC
directly activates eIF4E in SCLC cells by an mTOR-
independent bypassing pathway.
MYC is one of the most frequently activated onco-
genes and its expression correlates with poor prognosis
in several human cancers [23]. MYC family DNA ampli-
fication has frequently been observed in SCLC patientsand corresponding cell lines [24,25]. MYC amplification
is also associated with poor survival in SCLC patients
[24]. These findings suggest that MYC may be a driver
gene and may constitute a possible avenue for therapeutic
intervention in SCLC. MYC protein is a transcription
factor that activates expression of many genes through
binding on consensus sequences. MYC is considered to
regulate the expression of 15% of all genes. However,
despite the importance of MYC signaling in SCLC,
MYC targets corresponding to drug resistance have not
been fully clarified.
Our study showed that MYC directly activates eIF4E
and contributes to drug resistance to everolimus in SCLC
cells. Activation of both MYC and eIF4E have been found
in human tumor cells [26,27]. A previous study reported
that human mammary epithelial cells carrying the PIK3CA
mutation showed acquired resistance to PI3K/mTOR in-
hibitor via the MYC-eIF4E axis [22]. The MYC-eIF4E axis
contributes to resistance to PI3K/mTOR inhibitor via
initiation of up-regulated cap-dependent translation [22].
In our study, reduction of MYC and eIF4E restored sensi-
tivity to everolimus in SBC5 R1 and SBC5 R10 cells as well
as in parent SBC5 cells. These findings suggest that assess-
ment of eIF4E expression levels is useful for assessment of
resistance to mTOR inhibitor, and control of the MYC-
eIF4E axis is a promising therapeutic strategy for mTOR
inhibition in SCLC.
Recently, aurora kinase inhibitors (AURKI) have
been shown to be effective in SCLC cells with MYC
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proteins have been reported [29,30]. In neuroblastoma,
aurora kinase A expression is correlated with MYC ampli-
fication and protects the MYC protein from degradation
[29,30]. Although the antitumor effect of everolimus was
limited in SCLC, AURKI combined with everolimus may
be useful for overcoming resistance to everolimus in SCLC
with MYC activation and may constitute a new thera-
peutic strategy.
Conclusion
In conclusion, eIF4E has been shown to be an important
factor in the resistance to everolimus in SCLC cells. Fur-
thermore, we found an important link between MYC and
mTOR-independent eIF4E during resistance to everoli-
mus in SCLC. Inhibition of the MYC-eIF4E axis may be a
novel therapeutic strategy for overcoming the resistance
to everolimus in SCLC with MYC overexpression. Fur-
ther studies should be undertaken to clarify the mech-
anism of the connection between MYC and eIF4E and
thereby establish a new therapeutic strategy for mTOR
inhibition in SCLC.
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